Pegasus Asset Management Inc. Has $7.01 Million Holdings in Eli Lilly and Company $LLY

Pegasus Asset Management Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 19.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,183 shares of the company’s stock after purchasing an additional 1,521 shares during the period. Eli Lilly and Company accounts for 2.2% of Pegasus Asset Management Inc.’s holdings, making the stock its 16th biggest position. Pegasus Asset Management Inc.’s holdings in Eli Lilly and Company were worth $7,007,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the second quarter worth about $29,000. Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company during the 2nd quarter valued at $31,000. Finally, Bare Financial Services Inc grew its position in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Leerink Partners set a $1,234.00 target price on shares of Eli Lilly and Company in a research note on Monday, January 5th. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $1,173.91.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly struck a partnership with Repertoire Immune Medicines worth up to $1.93 billion to develop therapies for multiple autoimmune diseases — expands pipeline and adds near‑term R&D optionality and milestone upside. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: LLY announced a major gene‑editing collaboration and licensing deal (reported ~$1.1B) with Seamless/Seamless Therapeutics to develop programmable recombinase‑based and other gene‑editing treatments, including hearing‑loss programs — further diversifies the pipeline beyond GLP‑1s. Eli Lilly (LLY) Inks $1.12 Billion Deal with ‘Gene-Editing’ Firm Seamless
• Positive Sentiment: Coverage highlights LLY’s push beyond GLP‑1s into oncology and gene editing (including an AI partnership to accelerate oncology R&D), signaling new growth vectors that support higher long‑term revenue potential. Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets
• Positive Sentiment: President Trump said Lilly plans to build six U.S. manufacturing plants — signals capacity expansion and potential supply resilience that investors view favorably for scaling demand. Trump says Eli Lilly to build six US plants
• Neutral Sentiment: Analyst and commentary pieces (bull case writeups) reiterate strong fundamentals and a bullish valuation thesis for LLY but are opinion‑driven rather than new corporate developments. Eli Lilly and Company (LLY): A Bull Case Theory
• Neutral Sentiment: Recent earnings and sector momentum have supported LLY’s multiple; analysts expect continued earnings strength into the next report (positive fundamental backdrop but largely already priced in). Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation
• Negative Sentiment: Medicare’s expanded drug‑price negotiation list includes Verzenio, raising potential pricing pressure on one of Lilly’s oncology products and creating earnings risk if negotiations materially reduce net pricing. Medicare is about to start negotiating the prices of medications administered by doctors
• Negative Sentiment: Some investors sold into the news: LLY shares briefly fell after the gene‑editing announcement, suggesting part of the market reaction is profit‑taking or that investors wanted clearer near‑term revenue visibility. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership
• Negative Sentiment: Competitive pressure in obesity/weight‑loss remains intense (Novo Nordisk is outspending Lilly on advertising), which could cap market share or force higher promotional costs. Novo Nordisk Is Spending Twice as Much as Eli Lilly (LLY) on Weight-Loss Drug Ads

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,023.81 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm has a market capitalization of $967.89 billion, a P/E ratio of 50.09, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The company’s 50-day moving average is $1,057.27 and its 200 day moving average is $887.02. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.